31.01.2017
B.R.A.I.N. Biotechnology Research And Information Network AG DE0005203947
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN proposes Supervisory Board candidates for election at its Annual General Meeting
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): AGM/EGM/Change of Personnel
B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN proposes
Supervisory Board candidates for election at its Annual General Meeting
31.01.2017 / 14:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
BRAIN proposes Supervisory Board candidates for election at its Annual
General Meeting
Zwingenberg, January 31, 2017: Today, B.R.A.I.N. Biotechnology Research and
Information Network AG ("BRAIN AG", ISIN DE0005203947 / WKN 520394) has
published the invitation for its first public Annual General Meeting as a
stock listed company, to be held on March 9, 2017, to its shareholders in
the electronic Federal Gazette (Bundesanzeiger) and on its website. Besides
other agenda items, four of the six Supervisory Board members of BRAIN AG
are to be newly elected during the General Meeting. While the term of
office of Professor Klaus-Peter Koller and Dr Holger Zinke regularly ends
with the end of the upcoming General Meeting, the Supervisory Board members
Siegfried Drueker and Dr Matthias Kromayer resign from their positions. In
addition to the re-election of the long-term Supervisory Board member
Professor Dr Klaus-Peter Koller, three new Supervisory Board candidates are
proposed for election to the Annual General Meeting.
The three new candidates are Dr Anna Eichhorn, Dr Martin Jager and Dr Georg
Kellinghusen. In selecting these three, the Supervisory Board has paid
particular attention to continuity, experience and necessary expertise,
with an additional focus on the indispensable industry, specialist and
business knowledge of the candidates, which are essential for the exercise
of the impending Supervisory Board mandates.
Dr Anna Eichhorn is an entrepreneur in the field of molecular diagnostics
and a proven specialist in the translation of data on human genetics into
the development of active ingredients. Dr Martin Jager has extensive and
long-standing international experience in the development and marketing of
new natural products and food ingredients. The expertise of Dr Georg
Kellinghusen as a recognised financial expert is based on his 30 years of
CFO work in various listed companies as well as his former membership in
the Supervisory Board of BRAIN AG. Furthermore, Professor Dr Klaus-Peter
Koller with his industrial expertise at the interface of research,
development and production of new biological products will continue to
benefit BRAIN.
The election proposals to the Annual General Meeting are consistent with
the objectives adopted by the Supervisory Board regarding its composition.
In the opinion of the Supervisory Board, all candidates are highly familiar
with the sector in which the Company operates.
The Chairman of the Supervisory Board and the entire Management Board of
the Company wish to thank Siegfried Drueker, Dr Matthias Kromayer and Dr
Holger Zinke, who will leave the BRAIN Supervisory Board at the end of the
Annual General Meeting on March 9, 2017, for the long-standing, successful
and always trustworthy cooperation.
Further details on the Annual General Meeting as well as on the election
proposals for the Supervisory Board are available on the website under
www.brain-biotech.de/en/investor-relations/general-meetings.
About BRAIN
BRAIN is one of Europe's leading technology companies in the field of
industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN
identifies previously untapped, efficient enzymes, microbial producer
organisms or natural substances from complex biological systems that can be
put to industrial use. The innovative solutions and products developed by
help of this "Toolbox of Nature" are successfully applied in the chemistry,
the cosmetics and the food industries. Today, BRAIN's business model is
based on two pillars - "BioScience" and "BioIndustrial". The first pillar,
"BioScience", comprises its - frequently exclusive - collaboration business
with industrial partners. The second pillar "BioIndustrial" comprises the
development and commercialisation of BRAIN's own products and active
product components. Further information is available at www.brain-
biotech.de/en
Contact:
B.R.A.I.N
Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
Tel.: +49-6251-9331-16
Fax: +49-6251-9331-11
E-Mail: [email protected]
www.brain-biotech.de
Disclaimer
This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that
could cause actual results, performance or events to differ materially from
those expressed or implied in such statements. There are numerous factors
which could influence the future performance by and future developments at
BRAIN AG and the BRAIN group of companies. Such factors include, but are
not limited to, changes in the general economic and competitive
environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations,
in particular with respect to tax laws and regulations, and other factors.
BRAIN AG does not undertake any obligation to update or revise any forward-
looking statements.
---------------------------------------------------------------------------
31.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
540371 31.01.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
B.R.A.I.N. Biotechnology Research And Information Network AG ISIN: DE0005203947 können Sie bei EQS abrufen
Biotechnologie , 520394 , BNN , XETR:BNN